Cell and gene therapy strategies to eradicate HIV reservoirsSpragg, Chelsea; De Silva Feelixge, Harshana; Jerome, Keith R.Current Opinion in HIV and AIDS: July 2016 - Volume 11 - Issue 4 - p 442–449 doi: 10.1097/COH.0000000000000284 STRATEGIES FOR TARGETING RESIDUAL HIV INFECTION: Edited by Matthieu Perreau and Nicolas Chomont Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Highly active antiretroviral treatment has dramatically improved the prognosis for people living with HIV by preventing AIDS-related morbidity and mortality through profound suppression of viral replication. However, a long-lived viral reservoir persists in latently infected cells that harbor replication-competent HIV genomes. If therapy is discontinued, latently infected memory cells inevitably reactivate and produce infectious virus, resulting in viral rebound. The reservoir is the biggest obstacle to a cure of HIV. Recent findings This review summarizes significant advances of the past year in the development of cellular and gene therapies for HIV cure. In particular, we highlight work done on suppression or disruption of HIV coreceptors, vectored delivery of antibodies and antibody-like molecules, T-cell therapies and HIV genome disruption. Summary Several recent advancements in cellular and gene therapies have emerged at the forefront of HIV cure research, potentially having broad implications for the future of HIV treatment. aVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA bDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA Correspondence to Keith R. Jerome, MD, PhD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, E5-110, Seattle, WA 98109, USA. Tel: +1 206 667 6793; e-mail: firstname.lastname@example.org Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.